首頁 > 產品介紹 > POCT Fully Immunofluorescence Quantitative Analyzer, IFA-Q-1000

POCT Fully Immunofluorescence Quantitative Analyzer, IFA-Q-1000

  • POCT Fully Immunofluorescence Quantitative Analyzer, IFA-Q-1000
商品圖像

  • 商品資訊

    Description

    POCT Fully Quantitative Immunofluorescence Analyzer
    Most Stable Rare Earth Material Time-Resolved
    Immunofluorescence Methodology
    Top Quality POCT Immunofluorescence Platform
    Platform Features
    Sample Types: Serum, Whole Blood, Plasma, Fingertip Blood, Urine…
    Parameters:Diabetes,Kidney Function,Infection,Cardiac Function,Gastric Function…
    Comprehensive
    Various assays
    Comprehensive sample types
    Simple and Convenient
    Small size, space -saved, stacked incubators
    Convenient operation, no requirement for professional skills
    Accuracy
    Constant incubation, corruption prevention,
    low coefficient variance Precise quality control, accurate results
    Rapidity
    Point of care testing
    Instant results analysis in 10 seconds

    Specifications

    Subject Performance parameter
    Detection speed 10 sec/test
    Time of first result 5-15min
    Sample position 8 channel (stackable)
    LIS system Support ASTM and HL7
    Size(mm) 500x400x400mm
    Net/Gross Weight 8.5/9kg
    Control Embedded integrated machine
    Interface Graphical operation interface
    Status monitor Real-time intelligent monitoring
    Repeatability CV≤15%
    Fluorescence

     

    Rare Earth Fluorescence life-span is longer than Quantum
    Fluorescence with no disruption and high accuracy
    Fluorescent materials Life-span
    Fluorescent rare earth 714000 ns
    Quantum 20-50 ns
    Nonspecific fluorescent particle 1-10 ns

    Rare earth fluorescence has larger stokes shift, higher signal-to noise ratio (SNR) and higher sensitivity compared to other markers

    Rare earth fluorescence has high quantum yield, high fluorescent efficiency, and wide linear range

    Menu of assays

    Biomarkers Abbr. Specimen Instruction for Use Expected values Measuring range
    Inflammation Procalcitonin

     

     

    		 PCT Serum/Whole Blood lndicate sepsis and bacterial infection <0.05 ng/mL 0.05-100 ng/mL
    Full Range
    C-reactive Protein    		 CRP Plasma/Whole Blood Low risk of cardiovascular disease Medium risk of cardiovascular disease ·High risk of cardiovascular disease Detecting conventional inflammation hs-CRP:<1.0mg/L hs-CRP:1.0-3.0mg/L hs-CRP:>3.0mg/L CRP:≤10 mg/L 0.5-200 mg/L
    C-reactive Protein/Amyloid proteinase A 2-in-1 CRP/SAA Plasma/Whole Blood ·Low risk of cardiovascular disease ·Medium risk of cardiovascular disease
    ·High risk of cardiovascular disease Detecting conventional inflammation    		 hs-CRP: <10mg/L hs-CRP:1.0-3.0mg/L
    hs-CRP: >3.0mg/L CRP:≤10 mg/L    		 0.5-200 mg/L
    Immune Rheumatism 3-in-1 ASO/RF/CRP Serum/Plasma/
    Whole Blood    		 lndicators of systemic inflammation ·To assist in the diagnosis,classification and prognosis of rheumatoid arthritis ASO:≤200 IU/mL
    RF:≤20IU/mL
    CRP:≤10 mg/L    		 ASO:50-500 IU/mL
    RF:10-200 IU/mL
    CRP:0.5-200 mg/L
    *Anti cyclic citrullinated peptide antibody Anti-CCP Serum/Plasma/Whole Blood ·Assistant diagnostic indexe of rheumatoid arthritis s25 U/mL 25-1000 U/mL
    Cardiovascular Cardiac Troponin I cTnl Serum/Plasma/Whole Blood ·Diagnose AMI,risk stratification and evaluate prognosis Value markers of non ST segment elevation MI ≤0.3 ng/mL 0.1-50 ng/mL
    Creatine Kinase-MB CK-MB Serum/Plasma/Whole Blood ·Negative exclusion of early AMI; Detection of recurrence and thrombolytic therapy ≤5 ng/mL 1-100 ng/mL
    Myoglobin MYO Serum/Plasma/Whole Blood Early diagnosis of AMI s70 ng/mL 5-500 ng/mL
    Myocardial Infarction(MI) 3-in-1 cTnl/MYO/
    CK-MB    		 Serum/Plasma/Whole Blood Same as above 3 markers cTnl:≤03ng/mL MYO=70 ng/mL CK-MB:≤5ng/mL cTnl:01-50 ng/mL MYO:5-500 ng/mL CK-MB:1-100 ng/mL
    D-Dimer(D-Dimer) D-Dimer Plasma/Whole Blood Exclusion and diagnosis of venous thromboembolism ≤0.5 mg/L 0.1-10 mg/L
    N-terminal B-type natriuretic peptide NT-proBNP Serum/Plasma/Whole Blood Diagnosis heart failure,risk stratification and prognostic evaluation ≤300 pg/mL 50-35000 pg/mL
    *Lipoprotein-Associated Phospholipase A2 Lp-PLA2 Serum/Plasma/Whole Blood lndicating the stability of atherosclerotic plaque ·Predicting the risk of coronary heart disease and stroke s200ng/mL 20-1000 ng/mL
    *cTnl/NT-proBNP/D-Dimer 3-in-1 cTnl/
    NT-proBNP/
    D-Dimer    		 Plasma/Whole Blood Same as above 3 markers ctnl:s03ng/mL NT-proBNP:≤300 pg/mL D-Dimer:≤0.5 mg/L cTnl:01-50 ng/mL NT-proBNP:100-20000 pg/mL D-Dimer:0.1-10 mg/L
     

  • 商品Q&A

    • 提問者稱呼
    • 手機
    • 留言內容
    • 驗證碼
上一頁
TOP